Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Prostate cancer
Stage/Subtype:  recurrent prostate cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 96 for your search:
Start Over
Androgen Deprivation Therapy and Orteronel or Bicalutamide in Treating Patients with Newly Diagnosed Metastatic Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: S1216, NCI-2012-02876, SWOG-S1216, NCT01809691
A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CR102931, NCI-2013-02187, 2012-004322-24, ARN-509-003, NCT01946204
Enzalutamide with or without Abiraterone Acetate and Prednisone in Treating Patients with Castration-Resistant Metastatic Prostate Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A031201, NCI-2013-01737, CALGB-A031201, NCT01949337
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: MDV3100-14, NCI-2013-02393, NCT02003924
Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: SP005, NCI-2014-02085, 2012-002814-38, NCT02111577
Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer (ARAMIS)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 17712, NCI-2015-00347, 2013-003820-36, NCT02200614
An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR105505, NCI-2015-00725, 56021927PCR3001, NCT02257736
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: MDV3100-13, NCI-2015-00824, NCT02319837
Magnetic Resonance Spectroscopic Imaging in Finding Tumors in Patients with Stage I-III Prostate Cancer Planning to Undergo Prostate Surgery
Phase: Phase II, Phase I
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: 2006-0516, NCI-2011-00517, PC061612, NCT00464724
Calcitriol in Combination with Ketoconazole and Therapeutic Hydrocortisone in Treating Patients with Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 68905, NCI-2011-00129, RPCI-I-68905, NCT00536991
Zoptarelin Doxorubicin in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: 4P-09-9, NCI-2009-01418, NCT01240629
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IM-T-IMMU-132-01, NCI-2014-00136, NCT01631552
Cabozantinib-S-Malate, Docetaxel, and Prednisone in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-C-0204, NCI-2013-01554, 120204, P11901, P9243_A21PAMDREVW01, 9243, NCT01683994
Ipilimumab and Abiraterone Acetate in Treating Patients with Previously Untreated Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-120, NCI-2012-01878, c12-097, NCT01688492
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CR103305, NCI-2013-01912, ARN-509-002, NCT01790126
Alisertib, Abiraterone Acetate, and Prednisone in Treating Patients with Hormone-Resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13P.128, NCI-2013-00895, 2013-02, NCT01848067
PARP inhibitor BMN-673 in Treating Patients with Advanced Solid Tumors and BRCA Mutations
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-C-0015, NCI-2013-02371, 09-25-0099, 140015, P131220, P9510_A08PAMDREVW01, 9510, NCT01989546
Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: IRB13-0979, NCI-2013-02151, CDMRP-PC121149, NCT02012296
Hormone Therapy and Ipilimumab in Treating Patients with Advanced Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MC0253, NCI-2009-01214, NCT00170157
Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 to 85
Trial IDs: J07122, NCI-2010-02020, JHOC-J07122, JHOC-NA_00010227, NCT00670046
Phenelzine Sulfate and Docetaxel in Treating Patients with Prostate Cancer with Progressive Disease after First-Line Therapy with Docetaxel
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB00005688, NCI-2010-02037, 5688, MR00045508, OHSU-5688, SOL-09105-LM, NCT01253642
Ipilimumab in Combination with Androgen Suppression Therapy in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 5254, NCI-2011-03556, 08-004, BMS#CA184059, CA184059, MR00039104, OHSU-5254, NCT01498978
Abiraterone Acetate in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 7639, NCI-2011-03745, 0801, NCT01508234, NCT01503229
Trebananib and Abiraterone Acetate in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12C0079, NCI-2013-01535, 00003846, 120079, 751173, P11890, 9068, NCT01553188
Start Over